Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Mario Negri Institute for Pharmacological Research: Clinical Trials & FDA Approval Profile

Mario Negri Institute for Pharmacological Research (Global / Institutional) sponsors 26 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 7 active protocols (4 recruiting now), 9 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)38.5%
Median Closed Enrollment vs National (145 pts)32 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Mario Negri Institute for Pharmacological Research
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)26
Active Pipeline (Recruiting Now)7 (4)
Completed vs Stopped Early9 / 10 (38.5%)
Median Closed Actual Enrollment32 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Mario Negri Institute for Pharmacological Research
Hospital Research SiteLocationShared Protocols
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, MI3
Azienda Ospedaliero Universitaria di ParmaParma2
Fondazione IRCCS CA' Granda Ospedale Maggiore PoliclinicoMilan2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Mario Negri Institute for Pharmacological Research
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06680050Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- OligometastasePhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Mario Negri Institute for Pharmacological Research Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI